Special events other expenses 17,915 taxes/licenses 80 islands against cancer 7,551 expenses advertising and website 11,794 marketing materials 4,239 bank & credit card fees 66 supplies 1,023 travel 22,172 other expenses 104 total 64,944
Main program · fiscal year 2022
Sara's cure is the only non-profit representing clear cell sarcoma in the USA but we collaborate with others throughout the world to ensure our work is efficient, meaningful and impactful to the ccs family of patients and our champion clinicians. Throughout 2021 we have continued funding repurposed drug testing by working with our medical advisors and their labs. Our executive director serves on a… Read more
Sara's cure is the only non-profit representing clear cell sarcoma in the USA but we collaborate with others throughout the world to ensure our work is efficient, meaningful and impactful to the ccs family of patients and our champion clinicians. Throughout 2021 we have continued funding repurposed drug testing by working with our medical advisors and their labs. Our executive director serves on an fda repurposed drug testing task force that meets monthly. This strategic involvement with key leaders ensures that the time and money spent is put to its highest and best use. In November 2021 the first of its kind phase I/II ccs trial opened. This was done in collaboration with rafael (now cornerstone pharma), the fda, and most important the ccs family of patients. We partnered to do this by agreeing to provide financial support to patients in the form of travel reimbursement to help patients get to trial locations. We hired the national organization of rare disorders to manage the disbursement of funds to the ccs patients directly. We have helped several patients to date. The clinical trial is ongoing. We continue to build the registry with nord and finalized the data dictionary in dec 2021. We continue to support patients through referrals to sarcoma centers of excellence and to the doctors that champion the ccs research who work with us to support our mission. We attended the world orphan drug congress in August 2021 and had a ccs father/board member attend as well as our executive and scientific directors who also attended the nord and ctos sarcoma conferences virtually. The ccs family of patients continues to be the driving force within the organization and has been critical to actively and financially supporting the work we do by participating in focus groups, providing patient experience input and hosting fundraisers in their communities around the globe including online events and facebook fundraisers.
In the organization's own words to the IRS, shown for context. None of this affects the America's Best Score, and a Form 990 describes programs without measuring their results.
Tax filings by year
Financial data extracted from the Form 990 the organization filed with the IRS for each fiscal year. Revenue lines can exceed 100% when other items, such as fundraising event costs, are netted against total revenue.
Revenue$91,784Fiscal year 2024
Expenses$104,700Fiscal year 2024
Total assets—Fiscal year 2024
Total liabilities—Fiscal year 2024
Fiscal year ending December2024
Revenue$91,784
Expenses$104,700
Net income−$12,916
Net assets$51,801
Notable sources of revenue
Percent of total revenue
Contributions
$34,473
37.6%
Program services
—
—
Investment income
$3
0.0%
Other (net)
$57,308
62.4%
Assets / debt
Total assets
—
Total liabilities
—
Net assets
$51,801
Compensation
Not in our extract for this year.
Fiscal year ending December2022
Revenue$99,906
Expenses$105,129
Net income−$5,223
Net assets$91,017
Notable sources of revenue
Percent of total revenue
Contributions
$83,212
83.3%
Program services
—
—
Investment income
$1
0.0%
Other (net)
$16,693
16.7%
Assets / debt
Total assets
—
Total liabilities
—
Net assets
$91,017
Compensation
Not in our extract for this year.
About this data
Figures come from IRS Form 990 filings, through the IRS Exempt Organizations Business Master File (2026-11-09) and e-filed returns. Form 990 data typically lags 12–24 months behind an organization's fiscal year. Found an error?